Pressmeddelande -
DATA PRESENTED AT AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS SUPPORT EXUBERA EFFICACY AND SAFETY PROFILE IN TYPE 1 A AND TYPE 2 DIABETES
Se bifogat dokument.
Pressmeddelande -
Franzéngatan 6
112 51 Stockholm
Sverige